COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN PERU

被引：0
|
作者：
Elgart, J. F. [1 ]
Gonzalez, L. [1 ]
Prestes, M. [1 ]
Manrique, H. [2 ]
Solorzano, J. [3 ]
Gagliardino, J. J. [1 ]
机构：
[1] UNLP, CONICET, Ctr Endocrinol Expt & Aplicada, CENEXA, La Plata, Buenos Aires, Argentina
[2] Hosp Nacl Arzobispo Loayza, Lima, Peru
[3] AstraZeneca CAMCAR MAC, San Jose, Costa Rica
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1300
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB38
引用
收藏
页码：A203 / A203
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE-2 DIABETES MELLITUS IN SPAIN
    Capel, M.
    Pomares, E.
    Perez-Alcantara, F.
    Simon, S.
    [J]. VALUE IN HEALTH, 2020, 23 : S508 - S508
  • [2] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Charalampos Tzanetakos
    Nicholas Tentolouris
    Georgia Kourlaba
    Nikos Maniadakis
    [J]. Clinical Drug Investigation, 2016, 36 : 649 - 659
  • [3] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Vega-Hernandez, Gabriela
    Wojcik, Radek
    Schlueter, Max
    [J]. DIABETES THERAPY, 2017, 8 (03) : 513 - 530
  • [4] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Gabriela Vega-Hernandez
    Radek Wojcik
    Max Schlueter
    [J]. Diabetes Therapy, 2017, 8 : 513 - 530
  • [5] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Tentolouris, Nicholas
    Kourlaba, Georgia
    Maniadakis, Nikos
    [J]. CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 649 - 659
  • [6] COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN THE UK
    Schlueter, M.
    Vega-Hernandez, G.
    Wojcik, R.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A675 - A675
  • [7] The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Postema, R.
    Townsend, R.
    Roudaut, M.
    [J]. DIABETIC MEDICINE, 2015, 32 (07) : 890 - 898
  • [8] Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom
    Bennett, Hayley
    Tank, Amarjeet
    Evans, Marc
    Bergenheim, Klas
    McEwan, Phil
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (07): : 1047 - 1055
  • [9] LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN SPAIN: A COST-EFFECTIVENESS ANALYSIS
    de Arellano Serna, Ramirez A.
    Mezquita-Raya, P.
    Vega-Hernandez, G.
    Wojcik, R.
    Schlueter, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [10] The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
    van der Linden, N.
    Van Olst, S.
    Nekeman, S.
    Uyl-de Groot, C. A.
    [J]. DIABETIC MEDICINE, 2021, 38 (04)
12345